FORM 3

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

#### OMB APPROVAL OMB Number 3235-0104 Estimated average burden hours per response 0.5

# INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  KERINS PATRICK J			2. Date of Eve Requiring State (Month/Day/Ye	tement	3. Issuer Name and Ticker or Trading Symbol  Mersana Therapeutics, Inc. [ MRSN ]					
(Last) (First) (Middle)			06/27/2017		Relationship of Reporting Person(s) to Issuer (Check all applicable)			5. If Amendment, Date of Original Filed (Month/Day/Year)		
1954 GREENSPRING DRIVE SUITE 600					Director X Officer (give title below)	10% Owne Other (spec below)	6. Inc	6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person		
(Street) TIMONIUM MD 21093										
(City)	(State)	(Zip)								
Table I - Non-Derivative Securities Beneficially Owned										
1. Title of Security (Instr. 4)					Amount of Securities Beneficially Owned (Instr. 4)	3. Ownershi Form: Direct or Indirect (I (Instr. 5)	t (D) (Instr.		Beneficial Ownership	
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
Title of Derivative Security (Instr. 4)			2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securit Underlying Derivative Securit		4. Conversion or	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
			Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Exercise Price of Derivative Security	Direct (D) or Indirect (I) (Instr. 5)		
Series A-1 Pre	A-1 Preferred Stock		(1)	(1)	Common Stock	2,647,241	(1)	I	See Note 2 <sup>(2)</sup>	
Series B-1 Preferred Stock		(3)	(3)	Common Stock	4,000,314	(3)	I	See Note 2 <sup>(2)</sup>		
Series C-1 Preferred Stock		(4)	(4)	Common Stock	492,583	(4)	I	See Note 2 <sup>(2)</sup>		
Stock Purchase Warrant (right to buy)		09/27/2013	09/27/2023	Common Stock	70,593	0.05	I	See Note 2 <sup>(2)</sup>		

# Explanation of Responses:

- 1. The Series A-1 Convertible Preferred Stock is convertible into shares of common stock at any time at the holder's election and automatically upon the consummation of a public offering of the registrant. There is no expiration date for the Series A-1 Convertible Preferred Stock.
- 2. The Reporting Person is a director of NEA 14 GP, LTD, which is the sole general partner of NEA Partners 14, L.P. ("NEA Partners 14"). NEA Partners 14 is the sole general partner of New Enterprise Associates 14, L.P. ("NEA 14"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 shares in which the Reporting Person has no pecuniary interest.
- 3. The Series B-1 Convertible Preferred Stock is convertible into shares of common stock at any time at the holder's election and automatically upon the consummation of a public offering of the registrant. There is no expiration date for the Series B-1 Convertible Preferred Stock.
- 4. The Series C-1 Convertible Preferred Stock is convertible into shares of common stock at any time at the holder's election and automatically upon the consummation of a public offering of the registrant. There is no expiration date for the Series C-1 Convertible Preferred Stock

### Remarks:

/s/ Sasha Keough, attorney-in-06/27/2017 **fact** 

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.